Lineage Cell Therapeutics (LCTX) Divestments (2018)

Lineage Cell Therapeutics' (LCTX) quarterly Divestments came in at $3.2 million in Q1 2018.

Lineage Cell Therapeutics (LCTX) Divestments (2018) Analysis & Trends

Lineage Cell Therapeutics' Divestments history runs 1 years deep, the most recent figure standing at $3.2 million for Q1 2018.

On a quarterly basis, Divestments changed N/A year-over-year to $3.2 million in Q1 2018; TTM through Dec 2018 was $3.2 million, a N/A change from a year earlier, with the FY2018 full-year figure at $3.2 million, changed N/A from the prior year.
Divestments steadied at $3.2 million in Q1 2018 per LCTX's latest filing.
Across five years, Divestments topped out at $3.2 million in Q1 2018 and bottomed at $3.2 million in Q1 2018.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Divestments (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-32.58 Mn
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	-
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Lineage Cell Therapeutics	267.08 Mn	203.18 Mn	1.73 Mn	-

Historic Data

Download Data

Date	Value
Mar 31, 2018	3.22 Mn